Skip to content
PeptideTech
Cart

Home / Research library / TB-500 Fragment (17-23)

Peptides

TB-500 Fragment (17-23): molecular data, studies & sources

The selected analytical study describes an acetylated thymosin beta-4 active-region fragment under the name TB-500. It concerns detection in equine samples, not a human efficacy trial. A peptide fragment and full-length thymosin beta-4 are distinct identities.

Overview sources: PMID 23084823

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular record not yet resolved

A sufficiently specific molecular record was not resolved for this name. Formula, molecular weight and structure are withheld until the exact sequence, salt or preparation can be verified.

MF: not assigned · MW: not assigned · Structure: not assigned

Registered clinical trials

Studies registered on ClinicalTrials.gov that list TB-500 Fragment (17-23) as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

1 registered study matched, 1 currently active or recruiting.

By highest phase
Phase 2 · 1
By registry status
Recruiting · 1
StudyPhase · statusConditionsSponsor · size
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDNCT07487363 · start 2026-02-05 · primary completion 2027-02-14Phase 1 / Phase 2RecruitingAtherosclerotic Cardiovascular Diseases · Endothelial DysfunctionHudson Biotech80 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received TB-500 Fragment (17-23), with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

    Preclinical research, reviews & other publications

    Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

    1. Preclinical / laboratory research

      Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.

      Ho EN, Kwok WH, Lau MY et al. · Journal of chromatography. A · 2012

      Analytical detection of an acetylated thymosin beta-4 fragment in horse urine and plasma. This is not a human treatment trial.

      PMID 23084823 · DOI: 10.1016/j.chroma.2012.09.043

    TB-500 Fragment (17-23) supplier sources

    Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

    TB-500 Fragment (17-23) for sale: compare prices, sizes and forms from every tracked supplier →

    SupplierRecorded packagesExample source listing
    American PeptidesUSD10mg Vial1 recorded offers10mg Vial · $100.00Checked Oct 13, 2026Supplier listing, TB-500 Fragment (17-23) 10mg Vial, American Peptides, opens in a new tab
    Amino USAUSD10mg Vial1 recorded offers10mg Vial · $40.00Checked Oct 13, 2026Supplier listing, TB-500 Fragment (17-23) 10mg Vial, Amino USA, opens in a new tab

    Reference sources & further reading

      The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

      Search for additional research

      These links run searches; their results have not been individually reviewed and can include unrelated compounds.

      Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

      Related research profiles

      Peptides

      ARA-290

      C51H84N16O21

      1257.3 g/mol · PubChem CID 91810664

      7 selected publications · 3 human intervention studies · 2 registered trials

      Protein / peptide · highest stage: Phase 2

      Structure, studies & sources →

      Peptides

      BPC-157

      C62H98N16O22

      1419.5 g/mol · PubChem CID 9941957

      7 selected publications · 1 human intervention study · 3 registered trials

      Protein / peptide · highest stage: Phase 1

      Structure, studies & sources →